Pharmacokinetic Evaluation of a Single 5-Gram Bolus of Creatine Monohydrate Versus Two Other Creatine-Containing Investigational Products
Antonio J, Evans C, Jiannine L, Curtis J, Wojnas K, Burgess V, Willoughby D, Hohl C, Petersen B, Flynn S, Baisley J, Parekh G, Kalman D
Cureus · 1 citation
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- No health outcome
Who paid for it
- Funding
- Industry funded
- Authors
- At least one author declares a financial tie to industry
Based on full-text disclosure statement.
Publication
- Published
- 2022-04-22 · Cureus · vol. 14 · issue 4 · p. e24395
- Publisher
- Cureus, Inc.
- Cited
- 2 citations · more than 33% of similar papers · 0.1× the field average
- References
- 21 works
- Access
- Open access (free to publish) · CC-BY
- Research areas
- Muscle metabolism and nutrition · Diet and metabolism studies · Glycogen Storage Diseases and Myoclonus
- Keywords
- Cmax, Pharmacokinetics, Creatine, Creatine Monohydrate, Medicine, Ingestion, Area under the curve, Pharmacology, Animal science, Internal medicine, Biology, Placebo, Pathology
13 authors
From US, CA
- José AntónioNova Southeastern University
- Cassandra EvansNova Southeastern University
- Lia JiannineNova Southeastern University
- Jason CurtisKeiser University
- Katarzyna WojnasNova Southeastern University
- Victoria BurgessConcordia University Chicago
Abstract
The purpose of this study was to determine the relative pharmacokinetics of creatine monohydrate delivered as a formula or as a pure powder (all mixed in solution). A single 5 g bolus of creatine monohydrate was ingested as CreaBev 1, CreaBev 2, or creatine monohydrate. Participants we assigned a test product and monitored in a supervised laboratory setting for ingestion and all blood draws starting 30 min post-ingestion to the 6-h mark. Standard pharmacokinetic analysis was undertaken to determine relative maximum concentration (Cmax), time to maximum concentration (Tmax), and area under the curve (AUC) for the products. Cmax data indicate that CreaBev 1 10.55±4.10, CreaBev 2 15.45±5.48, and creatine monohydrate 12.77±4.0 nmol/h/μL. The Tmax analysis demonstrated CreaBev 1 1.20±1.01, CreaBev 2 1.23±0.65, and creatine monohydrate 0.91±0.2 h. The AUC data indicate that CreaBev 1 22.90±9.17, CreaBev 2 33.92±9.52, and creatine monohydrate 29.58±11.93 nmol/h/μL. When examining the data for pharmacokinetics, the AUC and Cmax pharmacokinetics were greatest for CreaBev 2 (p<0.021 and 0.020). Within the confines of this study, CreaBev 2 produced the highest blood concentrations of creatine as compared to creatine monohydrate and CreaBev 1.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.